Video

Ã…ge Schultz, DVM, PhD, Discusses the Cost of Supportive Care Medicine

Ã…ge Schultz, DVM, PhD, executive director, Multinational Association of Supportive Care in Cancer (MASCC), discusses pain management and the cost of supportive care medicine.

Åge Schultz, DVM, PhD, executive director, Multinational Association of Supportive Care in Cancer (MASCC), discusses pain management and the cost of supportive care medicine.

No patient with cancer should have pain, Schultz says. While morphine is one of the cheapest drugs in the world, officials in some countries are concerned with its potential for abuse. Today, many patients with cancer are living longer than ever before, so it is crucial that their side effects are treated.

In countries in the developed world, Schultz says, many patients can afford expensive medicines. In countries in the underdeveloped world, patients do not have access to these same drugs. As supportive care medicines are relatively inexpensive, Schultz says, it is in the interest of governments to support supportive care in order to help many people in a cheap way.

<<<

View more from the 2014 MASCC/ISOO Symposium

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School